MDT

82.4

-1.87%↓

VEEV

212.31

-1.28%↓

101.18

-3.47%↓

HQY

77.14

-4.78%↓

PDCO

31.14

+0.32%↑

MDT

82.4

-1.87%↓

VEEV

212.31

-1.28%↓

101.18

-3.47%↓

HQY

77.14

-4.78%↓

PDCO

31.14

+0.32%↑

MDT

82.4

-1.87%↓

VEEV

212.31

-1.28%↓

101.18

-3.47%↓

HQY

77.14

-4.78%↓

PDCO

31.14

+0.32%↑

MDT

82.4

-1.87%↓

VEEV

212.31

-1.28%↓

101.18

-3.47%↓

HQY

77.14

-4.78%↓

PDCO

31.14

+0.32%↑

MDT

82.4

-1.87%↓

VEEV

212.31

-1.28%↓

101.18

-3.47%↓

HQY

77.14

-4.78%↓

PDCO

31.14

+0.32%↑

Начало・Списък с акции・Iovance Biotherapeutics Inc

Iovance Biotherapeutics Inc

Затворен

СекторЗдравеопазване

3.02 0.67

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.69

Максимум

3.13

Ключови измерители
By Trading Economics
Приходи	5M -79M
Продажби	15M 74M
EPS	-0.26
Марж на печалбата	-106.602
Служители	838
EBITDA	14M -75M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+554.46% upside

Дивиденти
By Dow Jones
Следващи печалби	8.05.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-524M 1.2B
Предишно отваряне	2.35
Предишно затваряне	3.02

Настроения в новините

By Acuity

50%

173 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

2.95 / 3.2 Подкрепа & съпротива

Iovance Biotherapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.04.2025 г., 23:56 ч. UTC

Топ новини

Australian Consumer Confidence Firms Despite Market Falls

7.04.2025 г., 23:45 ч. UTC

Горещи акции

Stocks to Watch: CVS Health, UnitedHealth Group, Spire Global, Pacira BioSciences

7.04.2025 г., 21:36 ч. UTC

Значими двигатели на пазара

Medicare Insurer Shares Rise on Plans for Higher Payment Rates

7.04.2025 г., 21:11 ч. UTC

Значими двигатели на пазара

Broadcom Authorizes $10 Billion Share Repurchase Program

7.04.2025 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise After Recent Selloffs -- Market Talk

7.04.2025 г., 23:47 ч. UTC

Пазарно говорене

Gold Edges Lower Amid More Cautious Near-Term Outlook -- Market Talk

7.04.2025 г., 23:34 ч. UTC

Топ новини

Apple Users Rush to Upgrade iPhones Ahead of Potential Tariffs-Related Price Hikes -- WSJ

7.04.2025 г., 22:18 ч. UTC

Топ новини

Health Insurer Stocks Jump After Medicare Boosts Payment Rates -- Barrons.com

7.04.2025 г., 21:43 ч. UTC

Пазарно говорене

Oil Producers Choosing Returns Over Growth In Tariffs Fallout -- Market Talk

7.04.2025 г., 21:37 ч. UTC

Пазарно говорене

Canada Faces Financial Crisis-Like Symptoms That Rate Cuts Won't Cure -- Market Talk

7.04.2025 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

Infineon: All-Cash Transaction to Be Financed From Existing Liquidity and Additional Debt >IFX.FF

7.04.2025 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

Infineon: Transaction Combines Infineon's Portfolio for Automotive Microcontrollers With Automotive Ethernet Business of Marvell, Accelerating Infineon's System Capabilities for Software-Defined Vehicles >IFX.FF

7.04.2025 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

Infineon: Business Expected to Generate Rev of $225M-$250M in Calendar Yr 2025 With Gross Margin of Around 60% >IFX.FF

7.04.2025 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

Infineon: Enters Agreement for Acquisition of Marvell Technology's Automotive Ethernet Business for US$2.5 B >IFX.FF

7.04.2025 г., 21:31 ч. UTC

Топ новини

Apple Plans to Source More iPhones From India as Potential Tariff Fix -- Update

7.04.2025 г., 21:29 ч. UTC

Топ новини

PNC Names Former BlackRock Star Mark Wiedman as President -- WSJ

7.04.2025 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

Infineon Further Strengthens Its Number One Position In Automotive Microcontrollers And Boosts Systems Capabilities For Software-defined Vehicles With Acquisition Of Marvell's Automotive Ethernet Business >IFNNY MRVL

7.04.2025 г., 21:21 ч. UTC

Топ новини

Defense Stocks Can't Escape the Trade War. Expect to Hear This Term. -- Barrons.com

7.04.2025 г., 21:18 ч. UTC

Топ новини

Печалби

Levi Strauss Trying to Mitigate Tariff Impact on Consumer; Company Grows Revenue -- Update

7.04.2025 г., 21:17 ч. UTC

Печалби

Levi Sees U.S. Consumer 'Generally Resilient,' CFO Says

7.04.2025 г., 21:17 ч. UTC

Печалби

Levi Looking at Cost-Related Opportunities, Pricing Changes as Part of Response, CFO Says

7.04.2025 г., 21:16 ч. UTC

Печалби

Levi Strauss Sets Up Task Force to Understand Implications of Trump's Tariffs, CFO Singh Says

7.04.2025 г., 21:16 ч. UTC

Топ новини

What to Know About Trump's Latest Tariffs -- 3rd Update

7.04.2025 г., 21:15 ч. UTC

Придобивния, сливания и поглъщания

Marvell to Sell In-Vehicle Network Portfolio for $2.5B

7.04.2025 г., 21:14 ч. UTC

Топ новини

PNC Taps Ex-BlackRock Star Mark Wiedman as President -- WSJ

7.04.2025 г., 21:06 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

Trump Orders New Review of Nippon-U.S. Steel Merger -- 3rd Update

7.04.2025 г., 21:03 ч. UTC

Топ новини

Even Google Could Feel the Sting of a Trade War -- Barrons.com

7.04.2025 г., 20:59 ч. UTC

Топ новини

U.S. Stock Meltdown Gives Way to Global Rout -- WSJ

7.04.2025 г., 20:56 ч. UTC

Значими двигатели на пазара

Broadcom Authorizes $10B Share Repurchase Program

7.04.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Iovance Biotherapeutics Inc Прогноза

Ценова цел

By TipRanks

554.46% нагоре

12-месечна прогноза

Среден 19.83 USD 554.46%

Висок 32 USD

Нисък 6 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Iovance Biotherapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

13 ratings

Купи

Задържане

Продай

Според 13 анализатори, дали борсови рейтинги на Iovance Biotherapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

2.95 / 3.2Подкрепа & съпротива

Recent bullish events outweigh bearish events.

There are no events.

There is one bearish event.

Настроение

By Acuity

173 / 386 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.